Multiple Myeloma in 2023 Ways: From Trials to Real Life

Multiple Myeloma in 2023 Ways: From Trials to Real Life

Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clini...

Full description

Bibliographic Details
Main Authors: Manlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, Alessandro Allegra, Uroš Markovic, Cirino Botta, Fabrizio Accardi, Iolanda Donatella Vincelli, Salvatore Leotta, Federica Elia, Benedetta Esposito, Bruno Garibaldi, Gabriele Sapuppo, Alessandra Orofino, Alessandra Romano, Giuseppe A. Palumbo, Francesco Di Raimondo, Concetta Conticello
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Current Oncology
Subjects:
multiple myeloma
minimal residual disease
standard of care
daratumumab
autologous stem cell transplantation
frailty
Online Access:https://www.mdpi.com/1718-7729/30/11/705

Internet

https://www.mdpi.com/1718-7729/30/11/705

Similar Items